Provided by Tiger Trade Technology Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.26
0.0000
Volume:- -
Turnover:- -
Market Cap:8.92M
PE:-0.25
High:1.26
Open:1.26
Low:1.26
Close:1.26
52wk High:19.30
52wk Low:1.08
Shares:7.08M
Float Shares:6.23M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0074
EPS(LYR):-11.3504
ROE:-310.85%
ROA:-112.17%
PB:0.83
PE(LYR):-0.11

Loading ...

Hyperliquid Strategies Inc and Sonnet Biotherapeutics Holdings, Inc. Announce Closing of Business Combination

THOMSON REUTERS
·
Dec 03, 2025

Top Midday Decliners

MT Newswires Live
·
Dec 03, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM

Reuters
·
Dec 02, 2025

BRIEF-Sonnet Biotherapeutics Holdings Announces Stockholder Approval Of Proposed Business Combination With Hyperliquid Strategies

Reuters
·
Dec 02, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

GlobeNewswire
·
Nov 18, 2025

Are XRP, SOL Done? HYPE Pumps 10% On $1 Billion Treasury Raise

Benzinga
·
Oct 23, 2025

Sonnet BioTherapeutics, Spanios collaborate on non-clinical study of SON-1010

TIPRANKS
·
Oct 15, 2025

Sonnet Biotherapeutics Holdings Inc. Held Annual Meeting of Stockholders

Reuters
·
Sep 30, 2025

Many crypto-treasury companies are trading for less than what their digital assets are worth. Is this a bargain or a big red flag?

Dow Jones
·
Sep 27, 2025

Sonnet to Present at the MedInvest Biotech & Pharma Conference

GlobeNewswire
·
Sep 19, 2025

Top Premarket Decliners

MT Newswires Live
·
Sep 15, 2025

Sonnet Biotherapeutics Holdings Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Aug 27, 2025

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 14, 2025

Sonnet BioTherapeutics Q3 EPS $(0.95) Misses $(0.49) Estimate

Benzinga
·
Aug 14, 2025

Sonnet Releases Virtual Investor "What This Means" Segment

GlobeNewswire
·
Aug 11, 2025

Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
Aug 09, 2025

Sonnet Biotherapeutics Expands Clinical Evaluation of Son-1010 Dose Escalation With Atezolizumab in Ovarian Cancer

THOMSON REUTERS
·
Aug 04, 2025

Sonnet Biotherapeutics Holdings Inc - Topline Data Show Strong Potential for Son-1010 Benefit

THOMSON REUTERS
·
Aug 04, 2025

Sonnet Biotherapeutics Holdings Inc - Top Line Readouts Expected in Q4 2025

THOMSON REUTERS
·
Aug 04, 2025

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

GlobeNewswire
·
Aug 04, 2025